Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Drug response prediction in high-risk multiple myeloma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Assessing the miRNA sponge potential of RUNX1T1 in t(8;21) acute myeloid leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk patients by GEP70 treated in Total Therapy 2 and 3A have a progression-free survival (PFS) of more than 10years. We used available GEP data from high-risk patients by GEP70 at diagnosis from Total Therapy 2 and 3A to predict the response by the DRP score of drugs used in the treatment of myeloma patients. The DRP score stratified patients further. High-risk myeloma with a predicted sensitivity to melphalan by the DRP score had a prolonged PFS, HR=2.4 (1.2-4.9, P=0.014) and those with predicted sensitivity to bortezomib had a HR 5.7 (1.2-27, P=0.027). In case of predicted sensitivity to bortezomib, a better response to treatment was found (P=0.022). This method may provide us with a tool for identifying candidates for effective personalized medicine and spare potential non-responders from suffering toxicity.

Original languageEnglish
Pages (from-to)80-86
Number of pages7
Publication statusPublished - 20 Feb 2018

    Research areas

  • Antineoplastic Agents, Bortezomib, Disease-Free Survival, Gene Expression Profiling, Humans, Multiple Myeloma, Transcriptome, Clinical Trial, Phase III, Journal Article

ID: 52710787